Abstract
To investigate the dose-response relationship of semaglutide versus placebo and open-label liraglutide in terms of glycemic control in patients with type 2 diabetes.
Conclusions
After 12 weeks, semaglutide dose-dependently reduced HbA1c level and weight in patients with type 2 diabetes. No unexpected safety or tolerability concerns were identified; gastrointestinal AEs typical of glucagon-like peptide 1 receptor agonists were mitigated by dose escalation. On this basis, weekly semaglutide doses of 0.5 and 1.0 mg with a...
Authors
Michael A Nauck, John R Petrie, Giorgio Sesti, Edoardo Mannucci, Jean-Pierre Courrèges, Marie L Lindegaard, Christine B Jensen, Study 1821 Investigators
Volume
Vol. 39, No. 2, pp. 231-241
.jpg/500px-Ozempic_(53899794358).jpg)